Global surveillance 2018-2020
Conducted by Venatorx
Countries: Argentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Kuwait, Latvia, Lithuania, Malaysia, Mexico, Morocco, Netherlands, New Zealand, Nigeria, Panama, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Venezuela, Vietnam
To determine AMR rates in key gram-negative pathogens from global sites
|Protocol Summary||Study organisms were clinical isolates previously collected and frozen at -70°C. Isolates were from documented infections (clinically relevant causative agent), with only one isolate per species per patient allowed. Isolates were from community- and hospital-associated infection sources, distributed globally (>250 sites; >50 countries) with a focus on the United States (for 2018-2020: 22.4% of total) and Europe (for 2018-2020: 42.1% of total). Patient locations included: General Medicine; Medical ICU; Surgery General; Surgery ICU; Emergency Room; Pediatric ICU; General ICU; and Pediatric General. Isolates were sourced from: respiratory tract infections, urinary tract infections, bloodstream infections, intraabdominal infections, and skin/soft tissue infections. Organisms included Enterobacterales (for 2018-2020: n=13,731), Pseudomonas aeruginosa (for 2018-2020: n=4,619), Stenotrophomonas maltophilia (for 2018-2020: n=298) and methicillin-susceptible Staphylococcus aureus (for 2018-2020: MSSA; n=140). The identities of all isolates were confirmed using MALDI-TOF mass spectrometry. Broth microdilution MICs were determined using the ISO 20776-1:2019/CLSI M07 11th Ed. reference method. Quality control (QC) testing was performed each day of testing (CLSI M100).
Inclusions: human infection (clinically relevant causative agent), one isolate per infection episode; Exclusions: screening/carriage isolates, multiple isolates per infection episode.
|Isolates collection method||Clinically relevant causative agent only; one isolate per infection episode.|
|Types of surveillance||Prevalence-based|
|Number of Isolates||18,788|
|Contains pediatric data?||Yes|
|Contains genotype data?||No|
|Date Last Updated||31-Dec-2020|
|Expected frequency of updates to the dataset||To be determined|
|Publications||Link to (surveillance) posters on Venatorx corporate website provided here: www.venatorx.com|